文章摘要

ABO 血型为肺腺癌患者生存的预后因子

作者: 1郑燕, 1,2秦建军, 1刘先本, 1邢文群, 1张瑞祥, 1王总飞, 1,2陈先凯, 1,2李印
1 郑州大学附属肿瘤医院/河南省肿瘤医院胸外科，郑州 450000
2 中国医学科学院肿瘤医院胸外科，北京 100021
通讯: 李印 Email: liyin0825@hotmail.com
DOI: 10.3978/j.issn.2095-6959.2018.07.014
基金: 河南省高等学校重点科研项目(17A320048)；吴阶平基金(320.6799.15062，320.2730.1892)。

摘要

目的：分析ABO血型与肺腺癌根治切除术后患者临床病理资料的关系，以及能否预测生存。 方法：回顾性分析郑州大学附属肿瘤医院胸外科2015年10月1日到2016年12月31日连续177例接受 根治切除手术的肺腺癌病例，应用卡方检验评估ABO血型与临床病理资料的关系，应用Kaplan- Meier生存分析及Cox比例风险回归模型分析不同ABO血型对总生存的预后价值。结果：ABO血型 与根治术后腺癌患者临床病理特征无显著相关性。单因素及多因素分析显示O型血腺癌患者总生 存显著劣于非O型血患者(HR=0.314，95%CI：0.071~0.929，P=0.043)。结论：ABO血型与根治术 后肺腺癌患者生存相关，O型血患者总生存短于非O型血患者。
关键词： 肺腺癌；ABO血型；预后因子

ABO blood group is a predictor of survival in patients with adenocarcinoma of lung

Authors: 1ZHENG Yan, 1,2QIN Jianjun, 1LIU Xianben, 1XING Wenqun, 1ZHANG Ruixiang, 1WANG Zongfei, 1,2CHEN Xiankai, 1,2LI Yin
1 Department of Thoracic Surgery, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450000, China
2 Department of Thoracic Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China

CorrespondingAuthor: LI Yin Email: liyin0825@hotmail.com

DOI: 10.3978/j.issn.2095-6959.2018.07.014

Foundation: This work was supported by the Key Research Project from Henan Provincial High Schools (17A320048) and Wu Jieping Fund (320.6799.15062, 320.2730.1892)

Abstract

Objective: To evaluate the association between the ABO blood group and clinicopathologic characteristics in patients with adenocarcinoma of lung after radical surgery and whether the ABO blood group was associated with prognosis. Methods: We retrospectively analyzed the 177 consecutive patients with adenocarcinoma of lung who underwent curative surgical treatment at The Affiliated Cancer Hospital of Zhengzhou University between October 1, 2015 and December 31, 2016. The Chi-square test was adopted to evaluate the relationship between the ABO blood group and clinicopathologic characteristics. The prognostic value of ABO blood group on overall survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. Results: There was no significant association between the ABO blood group and clinicopathologic characteristics. Univariate and multivariate analyses showed that the overall survival of patients with blood type O was significantly worse than that of patients with blood type non-O (HR =0.314, 95% CI: 0.071–0.929, P=0.043). Conclusion: The ABO blood group is associated with survival in patients with lung adenocarcinoma after radical surgery. Patients with
blood type O have significantly shorter overall survival than patients with blood type non-O.
Keywords： adenocarcinoma of lung; the ABO blood group; prognostic factor

文章选项

下载引文

分享